Cite
HARVARD Citation
Schadendorf, D. et al. (2016). Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European journal of cancer. pp. 46-54. [Online].